Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments

Area of Science:

• Oncology
• Nanotechnology
• Biomedical Engineering

Background:

• Conventional cancer treatments like chemotherapy and anti-angiogenic therapies face challenges with tumor resistance.
• Tumor resistance is often driven by the tumor microenvironment, including hypoxia and cellular factors.
• There is a significant need for novel therapeutic strategies to overcome cancer treatment resistance.

Purpose of the Study:

• To review current cancer treatment strategies, focusing on hypoxia and emerging drug delivery systems.
• To explore the potential of nanoparticle (NP)-based therapies for improved cancer treatment.
• To discuss the use of mesenchymal stem cells (MSCs) as cellular vehicles for targeted NP delivery.

Main Methods:

• Review of existing literature on cancer therapies, nanoparticle drug delivery, and stem cell applications.
• Analysis of the role of the tumor microenvironment, particularly hypoxia, in treatment resistance.
• Examination of strategies for enhancing NP delivery using cellular carriers like MSCs, exosomes, and cell membranes.

Main Results:

• Nanoparticle-based therapies offer improved efficacy and targeting while reducing toxicity compared to conventional methods.
• Internalizing or conjugating drug-loaded NPs into MSCs enhances drug accumulation at tumor sites.
• Exosomes and cell membranes can also serve as effective carriers for drug-loaded NPs, overcoming MSC limitations.

Conclusions:

• Nanoengineering MSCs with drug-loaded NPs presents a promising strategy for targeted cancer therapy.
• The inherent migratory and homing abilities of MSCs facilitate efficient drug delivery to tumors.
• Alternative carriers like exosomes and cell membranes offer further potential for optimizing NP-based cancer treatments.